Literature DB >> 7477444

The non-peptide NK1 receptor antagonist SR140333 produces long-lasting inhibition of neurogenic inflammation, but does not influence acute chemo- or thermonociception in rats.

R Amann1, R Schuligoi, P Holzer, J Donnerer.   

Abstract

In anaesthetized rats, the neurokinin (NK)1 receptor antagonist SR140333 (10-1000 micrograms/kg) stereo-selectively inhibited mustard oil-induced plasma protein extravasation in the dorsal skin of the hind paw. After s.c. administration of SR140333, inhibition of plasma protein extravasation was maximal 3 h after injection. A dose of 0.1 mg/kg i.v. or 1.0 mg/kg s.c. produced long-lasting inhibition which was still significant 24 h after treatment. Since systemic administration of SR140333 has been shown to inhibit nociceptive responses in anaesthetized rats, we wanted to evaluate a possible effect of SR140333 on chemo- and thermonociception in conscious rats. SR140333 (100 micrograms/kg s.c.) did not reduce the behavioral response of rats to the irritant effect of capsaicin in the wiping test, nor did it affect the thermal nociceptive threshold in the plantar test. Furthermore, the decrease in thermal nociceptive threshold which was produced by intraplanter injection of PGE2, and which has been shown to be entirely dependent on capsaicin-sensitive afferents, was not affected by treatment with this NK1 receptor antagonist. These results show that systemic administration of SR140333, at doses which cause inhibition of neurogenic inflammation, has no detectable effect on acute chemo- or thermonociception in conscious rats.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7477444     DOI: 10.1007/bf00176775

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  25 in total

1.  Tachykinin receptor types: Classification and membrane signalling mechanisms.

Authors:  S Guard; S P Watson
Journal:  Neurochem Int       Date:  1991       Impact factor: 3.921

2.  Pharmacological properties of a potent and selective nonpeptide substance P antagonist.

Authors:  C Garret; A Carruette; V Fardin; S Moussaoui; J F Peyronel; J C Blanchard; P M Laduron
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

3.  Role of NK1 tachykinin receptors in thermonociception: effect of (+/-)-CP 96,345, a non-peptide substance P antagonist, on the hot plate test in mice.

Authors:  A Lecci; S Giuliani; R Patacchini; G Viti; C A Maggi
Journal:  Neurosci Lett       Date:  1991-08-19       Impact factor: 3.046

4.  Contribution of NK1 and NK2 receptor activation to high threshold afferent fibre evoked ventral root responses in the rat spinal cord in vitro.

Authors:  S W Thompson; L Urban; A Dray
Journal:  Brain Res       Date:  1993-10-15       Impact factor: 3.252

5.  Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin.

Authors:  N Jancsó; A Jancsó-Gábor; J Szolcsányi
Journal:  Br J Pharmacol Chemother       Date:  1967-09

6.  Neuropharmacological characterization of SR 140333, a non peptide antagonist of NK1 receptors.

Authors:  M Jung; R Calassi; J Maruani; M C Barnouin; J Souilhac; M Poncelet; C Gueudet; X Emonds-Alt; P Soubrié; J C Brelière
Journal:  Neuropharmacology       Date:  1994-02       Impact factor: 5.250

7.  Bradykinin-induced sensitization of afferent neurons in the rat paw.

Authors:  R Schuligoi; J Donnerer; R Amann
Journal:  Neuroscience       Date:  1994-03       Impact factor: 3.590

8.  Inhibition of neurogenic plasma exudation in guinea-pig airways by CP-96,345, a new non-peptide NK1 receptor antagonist.

Authors:  Y H Lei; P J Barnes; D F Rogers
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

9.  Decrease of substance P in primary afferent neurones and impairment of neurogenic plasma extravasation by capsaicin.

Authors:  R Gamse; P Holzer; F Lembeck
Journal:  Br J Pharmacol       Date:  1980-02       Impact factor: 8.739

Review 10.  Modulation of spinal excitability: co-operation between neurokinin and excitatory amino acid neurotransmitters.

Authors:  L Urban; S W Thompson; A Dray
Journal:  Trends Neurosci       Date:  1994-10       Impact factor: 13.837

View more
  8 in total

1.  Immunohistochemical localization of histamine H3 receptors in rodent skin, dorsal root ganglia, superior cervical ganglia, and spinal cord: potential antinociceptive targets.

Authors:  Keri E Cannon; Paul L Chazot; Victoria Hann; Fiona Shenton; Lindsay B Hough; Frank L Rice
Journal:  Pain       Date:  2006-11-28       Impact factor: 6.961

2.  Mechanisms of the cutaneous vasodilator response to local external pressure application in rats: involvement of CGRP, neurokinins, prostaglandins and NO.

Authors:  B Fromy; S Merzeau; P Abraham; J L Saumet
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

3.  Contribution of neurokinin 1 receptors in the cutaneous orofacial inflammatory pain.

Authors:  Philippe Luccarini; Mélaine Henry; Pedro Alvarez; Anne-Marie Gaydier; Radhouane Dallel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-09-27       Impact factor: 3.000

4.  A role for proteinase-activated receptor-1 in inflammatory bowel diseases.

Authors:  Nathalie Vergnolle; Laurie Cellars; Andrea Mencarelli; Giovanni Rizzo; Sunita Swaminathan; Paul Beck; Martin Steinhoff; Patricia Andrade-Gordon; Nigel W Bunnett; Morley D Hollenberg; John L Wallace; Giuseppe Cirino; Stefano Fiorucci
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

5.  Nociceptive afferent phenotyping reveals that transient receptor potential ankyrin 1 promotes cold pain through neurogenic inflammation upstream of the neurotrophic factor receptor GFRα3 and the menthol receptor transient receptor potential melastatin 8.

Authors:  Shanni Yamaki; Amanda Chau; Luigi Gonzales; David D McKemy
Journal:  Pain       Date:  2021-02-01       Impact factor: 6.961

6.  Prenatal nicotinic exposure upregulates pulmonary C-fiber NK1R expression to prolong pulmonary C-fiber-mediated apneic response.

Authors:  Lei Zhao; Jianguo Zhuang; Na Zang; Yong Lin; Lu-Yuan Lee; Fadi Xu
Journal:  Toxicol Appl Pharmacol       Date:  2015-10-30       Impact factor: 4.460

7.  TRPV1 activity and substance P release are required for corneal cold nociception.

Authors:  Fengxian Li; Weishan Yang; Haowu Jiang; Changxiong Guo; Andrew J W Huang; Hongzhen Hu; Qin Liu
Journal:  Nat Commun       Date:  2019-12-12       Impact factor: 14.919

8.  TRPM8: A Therapeutic Target for Neuroinflammatory Symptoms Induced by Severe Dry Eye Disease.

Authors:  Darine Fakih; Christophe Baudouin; Annabelle Réaux-Le Goazigo; Stéphane Mélik Parsadaniantz
Journal:  Int J Mol Sci       Date:  2020-11-19       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.